Cargando…

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

BACKGROUND: Current guidelines advise that rituximab or cyclophosphamide should be used for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), although few studies have examined the efficacy and safety of these agents in combination....

Descripción completa

Detalles Bibliográficos
Autores principales:	McAdoo, Stephen P, Medjeral-Thomas, Nicholas, Gopaluni, Seerapani, Tanna, Anisha, Mansfield, Nicholas, Galliford, Jack, Griffith, Megan, Levy, Jeremy, Cairns, Thomas D, Jayne, David, Salama, Alan D, Pusey, Charles D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322443/ https://www.ncbi.nlm.nih.gov/pubmed/29462348 http://dx.doi.org/10.1093/ndt/gfx378

Ejemplares similares

Clinical Trials in Vasculitis
por: Gopaluni, Seerapani, et al.
Publicado: (2016)

Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series
por: McAdoo, Stephen P., et al.
Publicado: (2016)

Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2018)

Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody
por: McAdoo, Stephen P., et al.
Publicado: (2011)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
por: McClure, Mark E., et al.
Publicado: (2023)

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial
por: Gopaluni, Seerapani, et al.
Publicado: (2017)

Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model
por: McAdoo, Stephen P., et al.
Publicado: (2020)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series
por: McAdoo, Stephen P., et al.
Publicado: (2015)

Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Prendecki, Maria, et al.
Publicado: (2022)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
por: Tieu, Joanna, et al.
Publicado: (2021)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)
por: Gopaluni, Seerapani, et al.
Publicado: (2022)

Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome
por: Trivioli, Giorgio, et al.
Publicado: (2020)

Anti–glomerular basement membrane disease during the COVID-19 pandemic
por: Prendecki, Maria, et al.
Publicado: (2020)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Salama, Alan D.
Publicado: (2019)

Membranous Glomerulonephritis With Crescents
por: Nikolopoulou, Aikaterini, et al.
Publicado: (2019)

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients
por: McAdoo, Stephen P., et al.
Publicado: (2017)

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
por: Austin, Keziah, et al.
Publicado: (2022)

Superior vena cava obstruction presenting with epistaxis, haemoptysis and gastro-intestinal haemorrhage in two men receiving haemodialysis with central venous catheters: two case reports
por: Gopaluni, Seerapani, et al.
Publicado: (2009)

Management of ANCA-associated vasculitis: Current trends and future prospects
por: Hamour, Sally, et al.
Publicado: (2010)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
por: Moog, Philipp, et al.
Publicado: (2015)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab
por: Boharoon, Hessa, et al.
Publicado: (2020)

ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
por: Austin, Keziah, et al.
Publicado: (2022)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
por: Latimer, Nicholas R., et al.
Publicado: (2014)

Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression
por: Prendecki, Maria, et al.
Publicado: (2020)

Glomerulonephritis and autoimmune vasculitis are independent of P2RX7 but may depend on alternative inflammasome pathways
por: Prendecki, Maria, et al.
Publicado: (2022)

Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report
por: Baird, Emily M, et al.
Publicado: (2011)

Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy
por: Yoneva, Tsvetelina, et al.
Publicado: (2022)

Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis
por: Pyo, Jung Yoon, et al.
Publicado: (2021)

Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization
por: Tempest-Roe, Shenzhen, et al.
Publicado: (2022)

An unusual case of familial cystic kidney disease
por: Gopaluni, Seerapani, et al.
Publicado: (2014)

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial
por: Merkel, Peter A, et al.
Publicado: (2020)

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Shah, Shivani, et al.
Publicado: (2017)

Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity
por: Prendecki, Maria, et al.
Publicado: (2016)

Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids
por: Prendecki, Maria, et al.
Publicado: (2017)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

Long- term outcome of paediatric patients with ANCA vasculitis
por: Arulkumaran, Nishkantha, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e6n2q1479ilcmkr4hiu640bp1q